Arginine Therapy: A New Treatment for Pulmonary Hypertension in Sickle Cell Disease?
The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Abstract
Pulmonary hypertension is a life-threatening complication of sickle cell disease. L-Arginine is the nitrogen donor for synthesis of nitric oxide, a potent vasodilator that is deficient during times of sickle cell crisis. This deficiency may play a role in pulmonary hypertension. The enzyme arginase hydrolyzes arginine to ornithine and urea, and thus, it may compete with nitric oxide synthase, leading to decreased nitric oxide production. Nitric oxide therapy by inhalation has improved pulmonary hypertension associated with acute chest syndrome in sickle cell disease, and several studies demonstrate therapeutic benefits of arginine therapy for primary and secondary pulmonary hypertension. We sought to determine the effects of arginine therapy on pulmonary hypertension in patients with sickle cell disease. Arginase activity was also determined. Oral arginine produced a 15.2% mean reduction in estimated pulmonary artery systolic pressure (63.9 +/- 13 to 54.2 +/- 12 mm Hg, p = 0.002) after 5 days of therapy in 10 patients. Arginase activity was elevated almost twofold (p = 0.07) in patients with pulmonary hypertension and may limit arginine bioavailability. With limited treatment options and a high mortality rate for patients with sickle cell disease who develop pulmonary hypertension, arginine is a promising new therapy that warrants further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical principles in experimental design.
Winer, B. J. (1962) · McGraw-Hill Book Company · doi:10.1037/11774-000 · Cited by 26,755
The L-Arginine-Nitric Oxide Pathway
Epstein, F. H., Moncada, S., & Higgs, A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292706 · Cited by 6,678
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320 · cited 1×
“Nitric oxide metabolism is altered during acute chest syndrome (42), a common pulmonary complication of sickle cell disease (43) associated with low plasma arginine (20) and nitric oxide metabolite levels (20, 44), that is also often accompanied by pulmonary hypertension.”
Arginine metabolism: nitric oxide and beyond
WU, G., & MORRIS, S. M. (1998) · Biochemical Journal · doi:10.1042/bj3360001 · Cited by 2,811
Self-citationBosentan Therapy for Pulmonary Arterial Hypertension
Rubin, L. J., Badesch, D. B., Barst, R. J., Galiè, N., Black, C. M., Keogh, A., Pulido, T., Frost, A., Roux, S., Leconte, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012212 · Cited by 2,726
De Caterina, R., Libby, P., Peng, H. B., Thannickal, V. J., Rajavashisth, T. B., Gimbrone, M. A., Shin, W. S., & Liao, J. K. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118074 · Cited by 1,782
Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease
Reiter, C. D., Wang, X., Tanus-Santos, J. E., Hogg, N., Cannon, R. O., Schechter, A. N., & Gladwin, M. T. (2002) · Nature Medicine · doi:10.1038/nm1202-799 · Cited by 1,330 · cited 3×
“Recent studies suggest that rapid scavenging of nitric oxide by cell-free hemoglobin, which is found in high concentrations under conditions of hemolysis, may limit nitric oxide bioavailability in sickle cell disease (13), while inhaled nitric oxide augments nitric oxide transport on sickle cell hemoglobin (14).”
Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension
PEPKEZABA, J. (1991) · The Lancet · doi:10.1016/0140-6736(91)92033-x · Cited by 1,055
Currie, P. J., Seward, J. B., Chan, K.-L., Fyfe, D. A., Hagler, D. J., Mair, D. D., Reeder, G. S., Nishimura, R. A., & Tajik, A. J. (1985) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(85)80477-0 · Cited by 1,002
L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans.
Creager, M. A., Gallagher, S. J., Girerd, X. J., Coleman, S. M., Dzau, V. J., & Cooke, J. P. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115987 · Cited by 813
Inhaled Nitric Oxide and Persistent Pulmonary Hypertension of the Newborn
Roberts, J. D., Fineman, J. R., Morin, F. C., Shaul, P. W., Rimar, S., Schreiber, M. D., Polin, R. A., Zwass, M. S., Zayek, M. M., Gross, I., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199702273360902 · Cited by 804
R EGULATION OF E NZYMES OF THE U REA C YCLE AND A RGININE M ETABOLISM
Morris, S. M. (2002) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.22.110801.140547 · Cited by 725
Self-citationXia, Y., Dawson, V. L., Dawson, T. M., Snyder, S. H., & Zweier, J. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.13.6770 · Cited by 718
N omega-hydroxy-L-arginine is an intermediate in the biosynthesis of nitric oxide from L-arginine.
Stuehr, D. J., Kwon, N. S., Nathan, C. F., Griffith, O. W., Feldman, P. L., & Wiseman, J. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)38112-2 · Cited by 575
Statistical Principles in Experimental Design, 2nd Edition.
Marascuilo, L. A., & Winer, B. J. (1973) · Journal of the American Statistical Association · doi:10.2307/2284115 · Cited by 548
A Short-Term Trial of Butyrate to Stimulate Fetal-Globin-Gene Expression in the β-Globin Disorders
Perrine, S. P., Ginder, G. D., Faller, D. V., Dover, G. H., Ikuta, T., Witkowska, H. E., Cai, S.-P., Vichinsky, E. P., & Olivieri, N. F. (1993) · New England Journal of Medicine · doi:10.1056/nejm199301143280202 · Cited by 437
Self-citationLong-term l -Arginine Supplementation Improves Small-Vessel Coronary Endothelial Function in Humans
Lerman, A., Burnett, J. C., Higano, S. T., McKinley, L. J., & Holmes, D. R. (1998) · Circulation · doi:10.1161/01.cir.97.21.2123 · Cited by 426
Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease
Aslan, M., Ryan, T. M., Adler, B., Townes, T. M., Parks, D. A., Thompson, J. A., Tousson, A., Gladwin, M. T., Patel, R. P., Tarpey, M. M., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.221292098 · Cited by 391 · cited 1×
“Superoxide, already increased in sickle cell disease (62) and augmented further by circulating xanthine oxidase (63) will consume nitric oxide to form the potent oxidant, peroxynitrite (64), further limiting nitric oxide bioavailability and possibly inducing cellular injury.”
Pieper, G. M. (1998) · Hypertension · doi:10.1161/01.hyp.31.5.1047 · Cited by 355
Regulation of Nitric Oxide Production by Arginine Metabolic Enzymes
Mori, M., & Gotoh, T. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3169 · Cited by 346
Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival
Castro, O., Hoque, M., & Brown, B. D. (2003) · Blood · doi:10.1182/blood-2002-03-0948 · Cited by 327
Boucher, J. L., Moali, C., & Tenu, J. P. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050352 · Cited by 316
Rector, T. S., Bank, A. J., Mullen, K. A., Tschumperlin, L. K., Sih, R., Pillai, K., & Kubo, S. H. (1996) · Circulation · doi:10.1161/01.cir.93.12.2135 · Cited by 275
Graido-Gonzalez, E., Doherty, J. C., Bergreen, E. W., Organ, G., Telfer, M., & McMillen, M. A. (1998) · Blood · doi:10.1182/blood.v92.7.2551 · Cited by 254
Differential regulation of arginases and inducible nitric oxide synthase in murine macrophage cells
Morris, S. M., Kepka-Lenhart, D., & Chen, L.-C. (1998) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1998.275.5.e740 · Cited by 252
Self-citationNitric oxide donor properties of hydroxyurea in patients with sickle cell disease
Gladwin, M. T., Shelhamer, J. H., Ognibene, F. P., Pease‐Fye, M. E., Nichols, J. S., Link, B., Patel, D. B., Jankowski, M. A., Pannell, L. K., Schechter, A. N., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03274.x · Cited by 234
Pearson, D. L., Dawling, S., Walsh, W. F., Haines, J. L., Christman, B. W., Bazyk, A., Scott, N., & Summar, M. L. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106143442404 · Cited by 229
KANEKO, F. T., ARROLIGA, A. C., DWEIK, R. A., COMHAIR, S. A., LASKOWSKI, D., OPPEDISANO, R., THOMASSEN, M. J., & ERZURUM, S. C. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.158.3.9802066 · Cited by 228 · cited 1×
“Endothelial dysfunction may contribute to the pathogenesis of pulmonary hypertension through impaired production of nitric oxide (7, 39-41).”
Morris, C. R., Kuypers, F. A., Larkin, S., Vichinsky, E. P., & Styles, L. A. (2000) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-200011000-00009 · Cited by 213
Self-citationArginine-Initiated Release of Human Growth Hormone: Factors Modifying the Response in Normal Man
Merimee, T. J., Rabinowitz, D., & Fineberg, S. E. (1969) · New England Journal of Medicine · doi:10.1056/nejm196906262802603 · Cited by 208
NAGAYA, N., UEMATSU, M., OYA, H., SATO, N., SAKAMAKI, F., KYOTANI, S., UENO, K., NAKANISHI, N., YAMAGISHI, M., & MIYATAKE, K. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.4.2007116 · Cited by 200
Sickle Cell Acute Chest Syndrome: Pathogenesis and Rationale for Treatment
Stuart, M. J., & Setty, B. N. Y. (1999) · Blood · doi:10.1182/blood.v94.5.1555 · Cited by 186
Pulmonary hypertension in sickle cell disease
Sutton, L. L., Castro, O., Cross, D. J., Spencer, J. E., & Lewis, J. F. (1994) · The American Journal of Cardiology · doi:10.1016/0002-9149(94)90760-9 · Cited by 184
Arnal, J. F., Münzel, T., Venema, R. C., James, N. L., Bai, C. L., Mitch, W. E., & Harrison, D. G. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117957 · Cited by 181
Short-term Pulmonary Vasodilation With l-Arginine in Pulmonary Hypertension
Mehta, S., Stewart, D. J., Langleben, D., & Levy, R. D. (1995) · Circulation · doi:10.1161/01.cir.92.6.1539 · Cited by 177
Role of Nitric Oxide in the Local Regulation of Pulmonary Vascular Resistance in Humans
Cooper, C. J., Landzberg, M. J., Anderson, T. J., Charbonneau, F., Creager, M. A., Ganz, P., & Selwyn, A. P. (1996) · Circulation · doi:10.1161/01.cir.93.2.266 · Cited by 154
Pozzoli, M., Capomolla, S., Pinna, G. D., Cobelli, F., & Tavazzi, L. (1996) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00553-6 · Cited by 146
Pulmonary hypertension and cor pulmonale in the sickle hemoglobinopathies
Collins, F. S., & Orringer, E. P. (1982) · The American Journal of Medicine · doi:10.1016/0002-9343(82)90763-x · Cited by 142
Inhaled Nitric Oxide in Sickle Cell Disease with Acute Chest Syndrome
Atz, A. M., & Wessel, D. L. (1997) · Anesthesiology · doi:10.1097/00000542-199710000-00037 · Cited by 142
Wound healing and thymotropic effects of arginine: a pituitary mechanism of action
Barbul, A., Rettura, G., Levenson, S. Μ., & SEIFTER, E. J. (1983) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/37.5.786 · Cited by 135
Gladwin, M. T., Schechter, A. N., Shelhamer, J. H., Pannell, L. K., Conway, D. A., Hrinczenko, B. W., Nichols, J. S., Pease-Fye, M. E., Noguchi, C. T., Rodgers, G. P., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7637 · Cited by 131
Plasma Growth Hormone after Arginine Infusion: Clinical Experiences
Merimee, T. J., Rabinowitz, D., Riggs, L., Burgess, J. A., Rimoin, D. L., & McKusick, V. A. (1967) · New England Journal of Medicine · doi:10.1056/nejm196702232760803 · Cited by 129
Tian, L., White, J. E., Lin, H.-Y., Haran, V. S., Sacco, J., Chikkappa, G., Davis, F. B., Davis, P. J., & Tsan, M.-F. (1998) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1998.275.3.c740 · Cited by 129
SYSTEMIC FAT EMBOLISM AND PULMONARY HYPERTENSION IN SICKLE CELL DISEASE
Castro, O. (1996) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70401-9 · Cited by 122 · cited 2×
“Anecdotal treatments with vasodilators, oxygen, anticoagulants and transfusion have been tried, but remain unproven (3, 5).”
Insulin and the arginine paradox.
Kurz, S. D., & Harrison, D. G. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119166 · Cited by 122
Endothelial function in different organs
Bassenge, E. (1996) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(96)80002-8 · Cited by 120
Glover, R. E., Ivy, E. D., Orringer, E. P., Maeda, H., & Mason, R. P. (1999) · Molecular Pharmacology · doi:10.1124/mol.55.6.1006 · Cited by 119
Sullivan, K., Goodwin, S. R., Evangelist, J., Moore, R. D., & Mehta, P. (1999) · Critical Care Medicine · doi:10.1097/00003246-199911000-00039 · Cited by 115
Endothelin-1 Production during the Acute Chest Syndrome in Sickle Cell Disease
HAMMERMAN, S. I., KOUREMBANAS, S., CONCA, T. J., TUCCI, M., BRAUER, M., & FARBER, H. W. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.156.1.9611085 · Cited by 113
Nitric Oxide Deficiency in Fenfluramine- and Dexfenfluramine-induced Pulmonary Hypertension
Archer, S. L., Djaballah, K., Humbert, M. J. C., Weir, Ε. K., Fartoukh, M. S., DALL'AVA-SANTUCCI, J., Mercier, J., Simonneau, G., & Dinh‐Xuan, A. T. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.158.4.9802113 · Cited by 112
Phelan, M., Perrine, S. P., Brauer, M., & Faller, D. V. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118102 · Cited by 109
Morris, C. R., Kuypers, F. A., Larkin, S. K., Sweeters, N., Simon, J., Vichinsky, E. P., & Styles, L. A. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02403.x · Cited by 104
Self-citationPulmonary Complications of Sickle Cell Anemia
Minter, K. R., & Gladwin, M. T. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.11.2104101 · Cited by 103
Ishizuka, T., Takamizawa‐Matsumoto, M., Suzuki, K., & Kurita, A. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00042-4 · Cited by 97
Peroxynitrite: A Putative Cytotoxin
Demiryürek, A. T., Çakıcı, İ., & Kanzık, İ. (1998) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1998.tb01408.x · Cited by 93
Renal nitric oxide synthases in transgenic sickle cell mice
Bank, N., Aynedjian, H. S., Qiu, J.-H., Osei, S. Y., Ahima, R. S., Fabry, M. E., & Nagel, R. L. (1996) · Kidney International · doi:10.1038/ki.1996.301 · Cited by 91
Nitric oxide therapy in sickle cell disease
Gladwin, M. T., & Schechter, A. N. (2001) · Seminars in Hematology · doi:10.1016/s0037-1963(01)90027-7 · Cited by 91
Arginine Deficiency Accompanies Persistent Pulmonary Hypertension of the Newborn
Vosatka, R. J., Kashyap, S., & Trifiletti, R. R. (2009) · Biology of the Neonate · doi:10.1159/000244091 · Cited by 90
Romero, J. R., Suzuka, S. M., Nagel, R. L., & Fabry, M. E. (2002) · Blood · doi:10.1182/blood.v99.4.1103 · Cited by 88
Moosmann, A., Khan, N., Cobbold, M., Zentz, C., Delecluse, H., Hollweck, G., Hislop, A. D., BLAKE, N. W., Croom-Carter, D. S. G., Wollenberg, B., et al. (2002) · Blood · doi:10.1182/blood.v100.5.1755.h81702001755_1755_1764 · Cited by 86
Homma, A., Anzueto, A., Peters, J. I., Susanto, I., Sako, E. Y., Zabalgoitia, M., Bryan, C. L., & Levine, S. M. (2001) · The Journal of Heart and Lung Transplantation · doi:10.1016/s1053-2498(01)00274-1 · Cited by 82
Regulation of Arginine Availability and Its Impact on NO Synthesis
Morris, S. M. (2000) · Elsevier eBooks · doi:10.1016/b978-012370420-7/50012-5 · Cited by 75
Self-citationAcute chest syndrome of sickle cell disease: new light on an old problem
Stuart, M. J., & Setty, Y. B. N. (2001) · Current Opinion in Hematology · doi:10.1097/00062752-200103000-00009 · Cited by 71
Gräf, P., Förstermann, U., & Closs, E. I. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703921 · Cited by 70
Dias‐da‐Motta, P. M., Arruda, V. R., Muscará, M. N., Saad, S. T. O., Nucci, G. D., Costa, F. F., & Condino‐Neto, A. (1996) · British Journal of Haematology · doi:10.1046/j.1365-2141.1996.4951036.x · Cited by 70
SULLIVAN, K. J., KISSOON, N., DUCKWORTH, L. J., SANDLER, E., FREEMAN, B., BAYNE, E., SYLVESTER, J. E., & LIMA, J. J. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.12.2012090 · Cited by 68
Measurement of hemoglobin saturation by oxygen in children and adolescents with sickle cell disease
Needleman, J. P., Setty, Y. B. N., Varlotta, L., Dampier, C., & Allen, J. L. (1999) · Pediatric Pulmonology · doi:10.1002/(sici)1099-0496(199912)28:6<423::aid-ppul7>3.0.co;2-c · Cited by 61
Nitric Oxide Metabolite Levels in Acute Vaso‐occlusive Sickle‐cell Crisis
Lopez, B. L., Barnett, J., Ballas, S. K., Christopher, T. A., Davis‐Moon, L., & Ma, X. (1996) · Academic Emergency Medicine · doi:10.1111/j.1553-2712.1996.tb03367.x · Cited by 61
Effect of L-Arginine Infusion on Infants with Persistent Pulmonary Hypertension of the Newborn
McCaffrey, M. J., Bose, C. L., Reiter, P. D., et al. (2009) · Biology of the Neonate · doi:10.1159/000244170 · Cited by 58
Zharikov, S. I., & Block, E. R. (2000) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.2000.278.1.l111 · Cited by 57
Perrine, S. P., Olivieri, N. F., Faller, D. V., Vichinsky, E. P., Dover, G., & Ginder, G. D. (1994) · PubMed · Cited by 56
Self-citationNitric Oxide Metabolites in Sickle Cell Anemia Patients after Oral Administration of Hydroxyurea
Nahavandi, M., Wyche, M. Q., Perlin, E., Tavakkoli, F., & Castro, O. (2000) · Hematology · doi:10.1080/10245332.2000.11746528 · Cited by 52
KLINGS, E. S., CHRISTMAN, B. W., McCLUNG, J., STUCCHI, A. F., McMAHON, L., BRAUER, M., & FARBER, H. W. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.7.2101020 · Cited by 46
Osei, S., Ahima, R., Fabry, M. E., Nagel, R. L., & Bank, N. (1996) · Blood · doi:10.1182/blood.v88.9.3583.bloodjournal8893583 · Cited by 36
Time resolved absorption study of the reaction of hydroxyurea with sickle cell hemoglobin
Kim‐Shapiro, D. B., King, S., Bonifant, C. L., Kolibash, C. P., & Ballas, S. K. (1998) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(97)00132-3 · Cited by 33
Evidence that L-arginine is a key amino acid in sickle cell anemia — A preliminary report
Waugh, W. H., Daeschner, C., Files, B. A., & Gordon, D. W. (1999) · Nutrition Research · doi:10.1016/s0271-5317(99)00017-2 · Cited by 29
Relationship between Arginase Activity and Nitric Oxide Production
Mori, M., & Gotoh, T. (2000) · Elsevier eBooks · doi:10.1016/b978-012370420-7/50013-7 · Cited by 16
Fatal Small-Bowel Necrosis and Pulmonary Hypertension in Sickle Cell Disease
Hammond, T. G., & Mosesson, M. W. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.1989.00390020137029 · Cited by 13
Cited by
Rees, D. C., Williams, T. N., & Gladwin, M. T. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61029-x · Cited by 2,504
Rother, R. P., Bell, L., Hillmen, P., & Gladwin, M. T. (2005) · JAMA · doi:10.1001/jama.293.13.1653 · Cited by 1,557
Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease
Gladwin, M. T., Sachdev, V., Jison, M. L., Shizukuda, Y., Plehn, J. F., Minter, K., Brown, B., Coles, W. A., Nichols, J. S., Ernst, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035477 · Cited by 1,325
Kato, G. J., Gladwin, M. T., & Steinberg, M. H. (2007) · Blood Reviews · doi:10.1016/j.blre.2006.07.001 · Cited by 876
Stuart, M. J., & Nagel, R. L. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17192-4 · Cited by 819
Metadata
- Authors
- Morris, C. R., Morris, S. M., Hagar, W., van Warmerdam, J., Claster, S., Kepka-Lenhart, D., Machado, L., Kuypers, F. A., & Vichinsky, E. P.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-07-01
- Volume
- 168
- Issue
- 1
- Pages
- 63-69
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2012026140
- Cited by
- 329
- References
- 78
- FWCI
- 10.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.